Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte (Q45919630)
Jump to navigation
Jump to search
scientific article published in July 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte |
scientific article published in July 2009 |
Statements
1 reference
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte (English)
1 reference
Jyoti D Patel
1 reference
Philip Bonomi
1 reference
Mark A Socinski
1 reference
Ramaswamy Govindan
1 reference
Shengyan Hong
1 reference
Coleman Obasaju
1 reference
Eduardo J Pennella
1 reference
Allicia C Girvan
1 reference
Susan C Guba
1 reference
1 July 2009
1 reference
1 reference
10
1 reference
4
1 reference
252-256
1 reference
Identifiers
1 reference
1 reference